[1] Ghanadan A, Kamyab K, Azhari VS, et al. Clinicopathological survey of 204 rosacea patients regarding rosacea subgroups and severity[J]. Dermatol Pract Concept, 2023,13:e2023182. doi: 10.5826/dpc.1303a182. [2] 马红,刘莉萍,李遇梅. 羟氯喹治疗玫瑰痤疮的疗效和安全性系统评价[J]. 中国美容医学,2024,33:70-75. [3] 李婷,胡阳,俞爱华,等. 口服青蒿琥酯治疗酒渣鼻31例临床观察[J]. 中国皮肤性病学杂志, 2015, 29: 330-332. [4] Yu R, Jin G, Fujimoto M. Dihydroartemisinin: a potential drug for the treatment of malignancies and inflammatory diseases[J]. Front Oncol, 2021,11:722331.doi:10.3389/fonc.2021.722331 [5] Casas C, Paul C, Lahfa M, et al. Quantification of demodex folliculorum by PCR in rosacea and its relationship to skin innate immune activation[J]. Exp Dermatol, 2012, 21:906-910. [6] Rodrigues-Braz D, Zhao M, Yesilirmak N, et al. Cutaneous and ocular rosacea: common and specific physiopathogenic mechanisms and study models[J]. Mol Vis, 2021,27:323-353. [7] Geng RSQ, Bourkas AN, Mufti A, et al. Rosacea: pathogenesis and therapeutic correlates[J]. J Cutan Med Surg, 2024,28:178-189. [8] Del Rosso JQ, Webster G, Weiss JS, et al. Nonantibiotic properties of tetracyclines in rosacea and their clinical implications[J]. J Clin Aesthet Dermatol, 2021,14:14-21. [9] 商妍,许文静,何俊辰,等. 青蒿功效的历史沿革[J]. 中国中西医结合皮肤性病学杂志,2024,23:461-464,470. doi:10.3969/j.issn.1672-0709.2024.05.024. [10] 周永婷,叶菜英,朱蕾. NLRP 3炎性小体激活调控机制及抑制剂研究新进展[J]. 基础医学与临床,2020,40:1113-1118. [11] Danis J, Mellett M. Nod-like receptors in host defence and disease at the epidermal barrier[J]. Int J Mol Sci, 2021, 22:4677. doi: 10.3390/ijms22094677. [12] Harden JL, Shih YH, Xu J, et al. Paired transcriptomic and proteomic analysis implicates IL-1βin the pathogene-sis of Papulopustular posacea explants[J]. J Invest Dermatol, 2021,141:800-809. [13] Agrahari G, Sah SK, Nguyen CT, et al. Superoxide dismutase 3 inhibits LL-37/KLK-5-mediated skin inflamma-tion through modulation of EGFR and associated inflammatory cascades[J]. J Invest Dermatol, 2020,140:656-665. [14] Kazmi STB, Fatima H, Naz I, et al. Pre-clinical studies comparing the anti-inflammatory potential of artemisinic compounds by targeting NFκB/TNF-α/NLRP3 and Nrf2/TRX pathways in Balb/C mice[J]. Front Pharmacol, 2024, 15:1352827. doi: 10.3389/fphar.2024.1352827. [15] Chen B, Li C, Chang G, et al. Dihydroartemisinin targets fibroblast growth factor receptor 1 (FGFR1) to inhibit interleukin 17A (IL-17A)-induced hyperproliferation and inflammation of keratinocytes[J]. Bioengineered,2022,13:1530-1540. |